Tag Archives: Additional

Study provides insight into spatial repellents as method to reduce infection of vector-borne diseases, encourages additional research

by Jessica Sieff A new report from the World Health Organization says initial results from a five-year study into the efficacy of spatial repellents encourage further research into their potential impact to reduce infection of vector-borne diseases including malaria, Zika and dengue fever. According to researchers at the University of Notre Dame, data from a clinical trial… Read More »

KemPharm Announces FDA Approval of sNDA for Two Additional Strengths of Apadaz (4.08 mg benzhydrocodone/325 mg APAP and 8.16 mg benzhydrocodone/325 mg APAP)

Print this page CORALVILLE, Iowa, Jan. 07, 2019 (GLOBE NEWSWIRE) — KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today that the U.S. Food and Drug Administration (FDA) has approved a Supplemental New Drug Application (sNDA) for two additional strengths of Apadaz, an immediate release (IR)… Read More »